The estimated Net Worth of Gilbert H Kliman is at least $145 Million dollars as of 9 September 2024. Gilbert Kliman owns over 3,000 units of Glaukos stock worth over $4,434,668 and over the last 9 years he sold GKOS stock worth over $140,565,329. In addition, he makes $238,256 as Director at Glaukos.
Sign up
Gilbert Kliman GKOS stock SEC Form 4 insiders trading
Gilbert has made over 14 trades of the Glaukos stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 3,000 units of GKOS stock worth $96,000 on 9 September 2024.
The largest trade he's ever made was selling 4,289,250 units of Glaukos stock on 28 June 2021 worth over $105,386,873. On average, Gilbert trades about 137,766 units every 44 days since 2015. As of 9 September 2024 he still owns at least 35,336 units of Glaukos stock.
You can see the complete history of Gilbert Kliman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Gilbert Kliman biography
Dr. Gilbert H. Kliman M.D. serves as Director of the Company. Dr. Kliman previously served on the Board from 2007 until his resignation on August 6, 2019 in connection with the Company’s acquisition of Avedro, Inc., upon which board of directors Dr. Kliman also served. Dr. Kliman has been a partner of InterWest Partners, a venture capital firm, since 1996, and has been a managing director there since 1999. Dr. Kliman served on the board of directors of Epocrates, Inc. (acquired by athenahealth, Inc.) from 1999 to 2011, and IntraLase Corp. (acquired by Advanced Medical Optics, Inc.) from 2000 to 2007. From 1995 to 1996, Dr. Kliman was an investment manager at Norwest Venture Partners, a venture capital firm. From 1989 to 1992, Dr. Kliman served as an associate at TA Associates, a private equity investment firm. Dr. Kliman is a board-certified ophthalmologist and completed a retina research fellowship at Massachusetts Eye and Ear Infirmary and residency training at Wills Eye Hospital. Dr. Kliman holds a B.A. from Harvard University, an M.D. from the University of Pennsylvania and an M.B.A. from the Stanford Graduate School of Business. Dr. Kliman currently serves as a director of a number of private life science and healthcare IT companies, and serves as a director on the executive board of ORBIS International, a global non-profit focused on preventing avoidable blindness.
What is the salary of Gilbert Kliman?
As the Director of Glaukos, the total compensation of Gilbert Kliman at Glaukos is $238,256. There are 9 executives at Glaukos getting paid more, with Thomas Burns having the highest compensation of $5,716,560.
How old is Gilbert Kliman?
Gilbert Kliman is 61, he's been the Director of Glaukos since 2020. There are 2 older and 8 younger executives at Glaukos. The oldest executive at Glaukos Corporation is William Link, 74, who is the Independent Chairman of the Board.
What's Gilbert Kliman's mailing address?
Gilbert's mailing address filed with the SEC is 25651, Atlantic Ocean Drive, Lake Forest, Orange County, California, 92630, United States.
Insiders trading at Glaukos
Over the last 11 years, insiders at Glaukos have traded over $300,254,118 worth of Glaukos stock and bought 17,376 units worth $317,262 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Gilbert H Kliman und Jonathan Silverstein. On average, Glaukos executives and independent directors trade stock every 25 days with the average trade being worth of $8,240,079. The most recent stock trade was executed by Gilbert H Kliman on 9 September 2024, trading 3,000 units of GKOS stock currently worth $96,000.
What does Glaukos do?
glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde
What does Glaukos's logo look like?
Complete history of Gilbert Kliman stock trades at Staar Surgical Co, Glaukos, Venus Concept und Doximity
Glaukos executives and stock owners
Glaukos executives and other stock owners filed with the SEC include:
-
Thomas Burns,
President, Chief Executive Officer, Director -
Chris Calcaterra,
Chief Operating Officer -
Joseph Gilliam,
Chief Financial Officer, Senior Vice President - Corporate Development -
Thomas William Burns,
Chairman, CEO & Pres -
Joseph E. Gilliam,
CFO & Sr. VP of Corp. Devel. -
Chris M. Calcaterra,
Chief Operating Officer -
William Link,
Independent Chairman of the Board -
Marc Stapley,
Independent Director -
Mark Foley,
Independent Director -
Aimee Weisner,
Independent Director -
David Hoffmeister,
Independent Director -
Gilbert Kliman,
Director -
L. Jay Katz,
Chief Medical Officer -
L. Jay Katz M.D., FACS,
Chief Medical Officer -
David S. Haffner,
Sr. VP of New Technologies -
Michele M. Allegretto,
Sr. VP of HR -
Diana A. Scherer,
VP of Compliance & Deputy Gen. Counsel -
Diane W. Biagianti,
Sr. VP & Gen. Counsel -
Christopher William Lewis,
Director of Investor Relations, Corp. Strategy & Devel. -
Dr. Mory Gharib Ph.D.,
Co-Founder -
Advisors Llc Orbi Med Capit...,
-
Advisors Llc Orbi Med Capit...,
-
Equity Partners Iv Lp Montr...,
-
Jonathan Silverstein,
Director -
Richard L Harrison,
Treasurer, CFO & Secretary -
Ventures I Llclubash Barbar...,
-
Ventures I Llcversant Ventu...,
-
Partners Iv Lpblair James C...,
-
Iv Associates Lpblair James...,
-
Viii Associates, L.P.Blair ...,
-
Management Partners Ix, Llc...,
-
Healthcare V, Lpfhm V, Llc ...,
-
Ventures I Llcversant Ventu...,
-
Robert J More,
Director -
Paul S Madera,
Director -
Olav Bergheim,
Director -
Ventures I Llcversant Ventu...,
-
Partners Viii, L.P.Blair Ja...,
-
Capital Associates Iii L.L....,
-
Alex R. Thurman,
SVP & CHIEF FINANCIAL OFFICER -
Tomas Navratil,
CHIEF DEVELOPMENT OFFICER -
Leana Wen,
-
Denice Torres,